Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial

BACKGROUND: Tumour necrosis factor inhibitors (TNFi) are effective in the treatment of patients with spondyloarthritis (SpA), including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). However, these drugs come with some disadvantages such as adverse events, practical burden for patien...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Trials
Glavni autori: Michielsens, Celia A. J., Boers, Nadine, den Broeder, Nathan, Wenink, Mark H., van der Maas, Aatke, Mahler, Elien A. M., Mulder, Michelle L. M., van der Heijde, Désirée, van den Hoogen, Frank H. J., Verhoef, Lise M., den Broeder, Alfons A.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2020
Teme:
Study Protocol
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964104/
https://ncbi.nlm.nih.gov/pubmed/31941544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-019-4000-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items